ArticleEJNMMI physics2026
A deep learning framework for lesion-level treatment response prediction in hodgkin lymphoma using PET/CT tensor radiomics.
Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prediction of treatment response in Hodgkin lymphoma (HL) is crucial for personalized therapy. The Tensor Radiomics (TR) paradigm advances traditional radiomics by producing and analyzing diverse feature variations, employing tensors computed across multiple parameter combinations to optimize radiomics feature extraction and improve tumor characterization. However, the complexity and variability of these features pose significant challenges for analysis and clinical application in HL research. This study introduces the Tensor Radiomics Network (TR-NET), a deep learning framework that automates feature selection from tensor radiomics data and predicts treatment response. It also incorporates explainable AI techniques to identify the most influential features.
methodsWe analyzed 420 lesions from 70 HL patients using
resultsTR-NET achieved a predictive performance, with an AUC-ROC of 0.8470 (95% CI: 0.7669-0.9185), a sensitivity of 82.2%, and a specificity of 78.2%, offering a balanced classification characteristic. In comparison, XGBoost achieved an AUC of 0.8160 (95% CI: 0.7457-0.8599), characterized by high sensitivity (93.3%) but lower specificity (66.2%), indicating a tendency towards false positives. Random Forest and SVM also showed high sensitivity (92% and 91.1%), but both suffered from significantly reduced specificity (29.5% and 51.3%).
conclusionTR-NET demonstrates enhanced predictive accuracy and clinical relevance compared to classic machine learning, supporting personalized treatment strategies and the integration of explainable AI in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.